149 related articles for article (PubMed ID: 2071476)
1. Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs.
Ogilvie GK; Vail DM; Klein MK; Powers BE; Dickinson K
J Am Vet Med Assoc; 1991 May; 198(10):1762-4. PubMed ID: 2071476
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Valerius KD; Ogilvie GK; Fettman MJ; Walton JA; Richardson K; Powers BE; McNiel EA; Rogers QR
J Am Vet Med Assoc; 1999 Feb; 214(3):353-6. PubMed ID: 10023395
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of mitoxantrone for the treatment of lymphoma in dogs.
Moore AS; Ogilvie GK; Ruslander D; Rand WS; Cotter SM; Getzy DM; L'Heureux DA; Dennis RA
J Am Vet Med Assoc; 1994 Jun; 204(12):1903-5. PubMed ID: 8077132
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of doxorubicin for treatment of various canine neoplasms.
Ogilvie GK; Reynolds HA; Richardson RC; Withrow SJ; Norris AM; Henderson RA; Klausner JS; Fowler JD; McCaw D
J Am Vet Med Assoc; 1989 Dec; 195(11):1580-3. PubMed ID: 2599941
[TBL] [Abstract][Full Text] [Related]
5. Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs.
Zenker I; Meichner K; Steinle K; Kessler M; Hirschberger J
Vet Rec; 2010 Nov; 167(19):744-8. PubMed ID: 21257510
[TBL] [Abstract][Full Text] [Related]
6. Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors.
Ogilvie GK; Obradovich JE; Elmslie RE; Vail DM; Moore AS; Curtis CR; Straw RC; Dickinson K; Cooper MF; Withrow SJ
J Am Vet Med Assoc; 1991 May; 198(9):1613-7. PubMed ID: 2061176
[TBL] [Abstract][Full Text] [Related]
7. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006).
Bannink EO; Sauerbrey ML; Mullins MN; Hauptman JG; Obradovich JE
J Am Vet Med Assoc; 2008 Aug; 233(3):446-51. PubMed ID: 18673031
[TBL] [Abstract][Full Text] [Related]
8. Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study.
Ogilvie GK; Moore AS; Chen C; Ciekot PA; Atwater SW; Bergman PJ; Walters LM
J Am Vet Med Assoc; 1994 Aug; 205(4):570-3. PubMed ID: 7961092
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma.
Khanna C; Lund EM; Redic KA; Hayden DW; Bell FW; Goulland EL; Klausner JS
J Am Vet Med Assoc; 1998 Oct; 213(7):985-90. PubMed ID: 9776993
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
Simon D; Moreno SN; Hirschberger J; Moritz A; Kohn B; Neumann S; Jurina K; Scharvogel S; Schwedes C; Reinacher M; Beyerbach M; Nolte I
J Am Vet Med Assoc; 2008 Mar; 232(6):879-85. PubMed ID: 18341445
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
12. Histologic classification as an indication of therapeutic response in malignant lymphoma of dogs.
Gray KN; Raulston GL; Gleiser CA; Jardine JH
J Am Vet Med Assoc; 1984 Apr; 184(7):814-7. PubMed ID: 6725115
[TBL] [Abstract][Full Text] [Related]
13. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB
Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245
[TBL] [Abstract][Full Text] [Related]
14. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors.
Ogilvie GK; Richardson RC; Curtis CR; Withrow SJ; Reynolds HA; Norris AM; Henderson RA; Klausner JS; Fowler JD; McCaw D
J Am Vet Med Assoc; 1989 Dec; 195(11):1584-7. PubMed ID: 2599942
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005).
Sauerbrey ML; Mullins MN; Bannink EO; Van Dorp TE; Kaneene JB; Obradovich JE
J Am Vet Med Assoc; 2007 Jun; 230(12):1866-9. PubMed ID: 17571992
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and toxicity of doxorubicin encapsulated in glutaraldehyde-treated erythrocytes administered to dogs with lymphosarcoma.
Matherne CM; Satterfield WC; Gasparini A; Tonetti M; Astroff AB; Schmidt RD; Rowe LD; DeLoach JR
Am J Vet Res; 1994 Jun; 55(6):847-53. PubMed ID: 7944027
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of mitoxantrone against various neoplasms in dogs.
Ogilvie GK; Obradovich JE; Elmslie RE; Vail DM; Moore AS; Straw RC; Dickinson K; Cooper MF; Withrow SJ
J Am Vet Med Assoc; 1991 May; 198(9):1618-21. PubMed ID: 2061177
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma.
Selting KA; Ogilvie GK; Gustafson DL; Long ME; Lana SE; Walton JA; Hansen RA; Turner AS; Laible I; Fettman MJ
Am J Vet Res; 2006 Jan; 67(1):145-51. PubMed ID: 16426224
[TBL] [Abstract][Full Text] [Related]
20. Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?
Marconato L; Bonfanti U; Stefanello D; Lorenzo MR; Romanelli G; Comazzi S; Zini E
Vet Comp Oncol; 2008 Jun; 6(2):80-9. PubMed ID: 19178667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
